These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19296063)

  • 1. A case of acute cardiomyopathy and pericarditis associated with methylphenidate.
    Dadfarmay S; Dixon J
    Cardiovasc Toxicol; 2009 Mar; 9(1):49-52. PubMed ID: 19296063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac arrest with pulseless electrical activity associated with methylphenidate in an adolescent with a normal baseline echocardiogram.
    Daly MW; Custer G; McLeay PD
    Pharmacotherapy; 2008 Nov; 28(11):1408-12. PubMed ID: 18957001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of methylphenidate.
    Daniels SR
    J Pediatr; 2009 Jul; 155(1):A3. PubMed ID: 19559283
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "A case of acute cardiomyopathy and pericarditis associated with methylphenidate"; Cardiovasc Toxicol, DOI 10.1007/s12012-009-9033-7.
    Ghanizadeh A
    Cardiovasc Toxicol; 2009 Jun; 9(2):105. PubMed ID: 19415530
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute myocardial infarction related to methylphenidate for adult attention deficit disorder.
    Thompson J; Thompson JR
    J Emerg Med; 2010 Jan; 38(1):18-21. PubMed ID: 18024065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.
    Ghanizadeh A
    J Pediatr Urol; 2008 Aug; 4(4):306-7. PubMed ID: 18644535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
    Hollis CP; Thompson A
    Pediatr Neurol; 2007 Oct; 37(4):287-8. PubMed ID: 17903675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients.
    Goldman W; Seltzer R; Reuman P
    Arthritis Rheum; 2008 Feb; 58(2):563-6. PubMed ID: 18240233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.
    Thomalla G; Kucinski T; Weiller C; Röther J
    World J Biol Psychiatry; 2006; 7(1):56-8. PubMed ID: 16428221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate induction of complex visual hallucinations.
    Halevy A; Shuper A
    J Child Neurol; 2009 Aug; 24(8):1005-7. PubMed ID: 19502578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.